| Major Depressive Disorder

Aplenzin vs Zoloft

Side-by-side clinical, coverage, and cost comparison for major depressive disorder.

Deep comparison between: Aplenzin vs Zoloft with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsZoloft has a higher rate of injection site reactions vs Aplenzin based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Zoloft but not Aplenzin, including UnitedHealthcare

Category

Aplenzin

Zoloft

At A Glance

RouteOral

FrequencyOnce daily

ClassNorepinephrine-dopamine reuptake inhibitor

RouteOral

FrequencyDaily

ClassSSRI

Indications

Major Depressive Disorder
Seasonal Affective Disorder

Major Depressive Disorder
Obsessive-Compulsive Disorder
Panic Disorder
Post-Traumatic Stress Disorder
Phobia, Social
Premenstrual Dysphoric Disorder

Dosing

Major Depressive Disorder Starting dose 174 mg once daily in the morning; after 4 days, increase to target dose of 348 mg once daily.

Seasonal Affective Disorder Starting dose 174 mg once daily; after 7 days, increase to target dose of 348 mg once daily in the morning; initiate in autumn, continue through winter, taper and discontinue in early spring.

Hepatic Impairment Moderate to severe (Child-Pugh 7-15): maximum 174 mg every other day; mild (Child-Pugh 5-6): consider reducing dose and/or frequency.

Renal Impairment Consider reducing dose and/or frequency in patients with GFR less than 90 mL/min.

Major Depressive Disorder Starting 50 mg/day orally; max 200 mg/day; titrate by 25-50 mg/day increments once weekly if inadequate response.

Obsessive-Compulsive Disorder Starting 25 mg/day (ages 6-12) or 50 mg/day (ages >=13) orally; max 200 mg/day; titrate by 25-50 mg/day increments once weekly if inadequate response.

Panic Disorder, Post-Traumatic Stress Disorder, Phobia, Social Starting 25 mg/day orally; max 200 mg/day; titrate by 25-50 mg/day increments once weekly if inadequate response.

Premenstrual Dysphoric Disorder Continuous dosing: starting 50 mg/day orally, max 150 mg/day; intermittent (luteal phase only): starting 50 mg/day, max 100 mg/day.

Contraindications

Seizure disorder
Current or prior diagnosis of bulimia or anorexia nervosa
Abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs
Concomitant use or use within 14 days of an MAOI intended to treat psychiatric disorders
Starting APLENZIN in a patient being treated with reversible MAOIs such as linezolid or intravenous methylene blue
Known hypersensitivity to bupropion or any ingredient of APLENZIN

Concomitant use or use within 14 days of stopping MAOIs, including linezolid and intravenous methylene blue, due to increased risk of serotonin syndrome
Concomitant use of pimozide
Known hypersensitivity to sertraline (e.g., anaphylaxis, angioedema)
Concomitant use of disulfiram with ZOLOFT oral solution (contains alcohol)

Drug Interactions

1228View drug interactions

1191View drug interactions

Adverse Reactions

Most common (>=5%) Anorexia, dry mouth, rash, sweating, tinnitus, tremor at 300 mg/day bupropion HCl SR equivalent; insomnia, headache, nausea, dizziness, constipation, anxiety also reported.

Serious Suicidal thoughts and behaviors, seizure, hypertension, activation of mania or hypomania, psychosis and other neuropsychiatric events, angle-closure glaucoma, hypersensitivity reactions including anaphylaxis and Stevens-Johnson Syndrome.

Postmarketing Stroke, complete atrioventricular block, myocardial infarction, Brugada pattern/syndrome, angioedema, DRESS, acute generalized exanthematous pustulosis, rhabdomyolysis, hepatitis, pancreatitis, aseptic meningitis.

Most common (>=5%) Nausea, diarrhea/loose stools, tremor, dyspepsia, decreased appetite, hyperhidrosis, ejaculation failure, decreased libido

Serious Suicidal thoughts and behaviors, serotonin syndrome, QTc prolongation and ventricular arrhythmias, increased risk of bleeding, activation of mania/hypomania, seizures, angle-closure glaucoma, hyponatremia, sexual dysfunction

Postmarketing Agranulocytosis, aplastic anemia, Stevens-Johnson Syndrome, toxic epidermal necrolysis, severe liver events including hepatitis and liver failure, QTc-interval prolongation, ventricular tachycardia, extrapyramidal symptoms, pulmonary hypertension, cerebrovascular spasm

Pharmacology

Bupropion is an aminoketone antidepressant whose action is presumed to be mediated by noradrenergic and/or dopaminergic mechanisms; it is a relatively weak inhibitor of neuronal norepinephrine and dopamine reuptake and does not inhibit MAO or serotonin reuptake.

Sertraline is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system through inhibition of neuronal reuptake of serotonin (5-HT), with only very weak effects on norepinephrine and dopamine reuptake and no significant affinity for adrenergic, cholinergic, GABA, dopaminergic, or histaminergic receptors; it does not inhibit monoamine oxidase.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Aplenzin